Teva launches generic migraine treatment


Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has launched generic treatment is for migraine, Axert (almotriptan malate) tablets in 6.25 mg and 12.5 mg dosages, in the US.

Teva is the first applicant to receive approval and will have a period of market exclusivity until the pediatric exclusivity associated with the only patent for Axert expires on November 7, 2015.

Teva continues to deliver on its generics business strategy and remains focused on increasing its first to file regulatory submissions in the US. With over 375 generic medicines available, Teva has the largest portfolio of safe, effective, US Food and Drug Administration (FDA) -approved generic products on the market.

Axert (almotriptan malate) tablets, marketed by Janssen Pharmaceuticals, had annual sales of approximately $31 million in the US, according to IMS data as of March 2015.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.